REG - Tristel PLC - Update on MobileODT strategic investment

TristelAnnouncement

18/11/2019 07:05

RNS Number : 6538T
Tristel PLC
18 November 2019
 


Tristel plc
("Tristel" of the "Company")
 
Update on MobileODT strategic investment
Completion of a second-round institutional funding
 
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that MobileODT ("MODT"), a company in which it holds a 2.13% strategic equity stake, has successfully completed its first closing of a US$9.75 million second-round institutional fund raising.  The funding has been led by OrbiMed Israel Partners and will provide MODT with further growth capital. Whilst Tristel has not participated in this latest funding round the Company has invested US$911,000 in MODT since June 2017.


MODT's Enhanced Visual Assessment (EVA) System is a smart colposcope used in over 40 countries. In the coming months MODT is expecting to launch its VisualPap AI, a visual analysis using the EVA System to assist clinicians make point-of-care diagnostic decisions for cervical cancer at a fraction of the time taken for comparable laboratory tests. For more information visit: www.mobileodt.com


Tristel enjoys a close strategic relationship with MODT, acting as distributor of the EVA System in the United Kingdom, Australia and New Zealand. Tristel has used its chlorine dioxide-based foam technology to develop the Duo EVE hand-held disinfectant as an accessory to the EVA colposcope. Furthermore, MODT has made a significant contribution to Tristel's development of 3T, a digital traceability system designed to train, track and trace the disinfection of medical devices.  It comprises a portal for setup, data management and reporting purposes and an App to record each step of the disinfection process.   


Paul Swinney, CEO, comments: "We made our first investment in MODT in June 2017 and during the past two years we have seen MODT make great strides in its development of machine learnt diagnosis of cervical cancer. This is a very important area of focus for Tristel as 97% of cervical cancers are caused by Human papilloma virus (HPV). Tristel's chlorine dioxide chemistry has been proven by leading experts to be one of only a few high-level disinfectants that can quickly and safely kill HPV on medical device surfaces. This provides a sizeable market opportunity for Tristel and is of enormous significance for colposcopes that are used to capture images of the cervix."
 
 
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
 
 
For further information please contact:       
 



Tristel plc


Tel: 01638 721 500




Paul Swinney, Chief Executive Officer








Liz Dixon, Finance Director


















Walbrook PR Ltd


Tel: 020 7933 8780 or tristel@walbrookpr.com




Paul McManus


Mob: 07980 541 893














finnCap


Tel: 020 7220 0500




Geoff Nash / Giles Rolls, Corporate Finance








Alice Lane, ECM


 



 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDCKPDDFBDDKDD